Other
Liquid biopsies
Liquid biopsies is an intervention with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
OTHER
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph not_applicable
3
100%
Phase Distribution
0
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution3 total trials
N/ANon-phased studies
3(100.0%)
Highest Phase Reached
UnknownTrial Status & Enrollment
Completion Rate
50.0%
1 of 2 finished
Non-Completion Rate
50.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(1)
Terminated(1)
Other(1)
Detailed Status
Withdrawn1
Completed1
unknown1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
N/A
Trials by Phase
N/A3 (100.0%)
Trials by Status
withdrawn133%
completed133%
unknown133%
Recent Activity
0 active trials
Showing 3 of 3
completednot_applicable
A Study to Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients with an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +- SSA Treatment
NCT05255133
withdrawnnot_applicable
Diagnostic and Prognostic Accuracy of FDHT-PET and Liquid Biopsies in Prostate Cancer
NCT05245435
unknownnot_applicable
A Study to Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients With an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +- SSA Treatment (Liquid-NET 2.0)
NCT05268952
Clinical Trials (3)
Showing 3 of 3 trials
NCT05255133Not Applicable
A Study to Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients with an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +- SSA Treatment
NCT05245435Not Applicable
Diagnostic and Prognostic Accuracy of FDHT-PET and Liquid Biopsies in Prostate Cancer
NCT05268952Not Applicable
A Study to Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients With an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +- SSA Treatment (Liquid-NET 2.0)
All 3 trials loaded
Drug Details
- Intervention Type
- OTHER
- Total Trials
- 3